FDA Approves Subcutaneous Leqembi for Treatment of Early Alzheimer Disease

TUESDAY, Sept. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly mai